ArticleInflammopharmacology2026
Ursolic acid, a pentacyclic triterpene from Ochrosia elliptica Labill leaves and its role in the management of polycystic ovary syndrome (PCOS).
Article in Inflammopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Hormonal Imbalance and Gut Dysbiosis: Emerging Perspectives in Women's Health.Probiotics and antimicrobial proteins · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ursolic Acid (UA), a naturally occurring pentacyclic triterpene, was isolated from Ochrosia elliptica. Polycystic Ovary Syndrome (PCOS) a prevalent endocrine disorder characterized by hyperandrogenism, insulin resistance, and chronic inflammation. In this study, we investigate the role of UA in alleviating the symptoms of PCOS, focusing on its biochemical, hormonal, and histopathological effects in a rat model. Using adult female Wistar Albino rats, PCOS was induced through letrozole administration. The rats were then treated with UA at two different doses (25 and 50 mg/kg), alongside a control group and a standard ovulation-inducing medication, clomiphene citrate (1 mg/kg). Biochemical analyses showed that PCOS induction significantly increased serum malondialdehyde (MDA) levels by approximately 1.21-fold, while markedly reducing superoxide dismutase (SOD) and catalase (CAT) activities (p ≤ 0.05) by approximately 0.48-fold, relative to negative control. Treatment with UA (50 mg/kg) dose-dependently restored oxidative balance, reducing MDA (~ 0.82-fold) and elevating SOD (~ 2.39-fold) and CAT (~ 2.11-fold) activities toward PCOS values (p ≤ 0.05). Hormonally, PCOS rats exhibited elevated luteinizing hormone (LH) and testosterone levels by approximately 1.70-fold, compared to the negative control (p ≤ 0.05). Both doses of UA significantly lowered LH and testosterone, with the 50 mg/kg dose achieving reductions comparable to clomiphene citrate (p ≤ 0.05). Histopathological examination showed improved ovarian morphology with reduced cystic follicles and increased corpus lutea in UA-treated groups. Furthermore, UA downregulated key genes involved in steroidogenesis and oxidative stress response, suggesting a multifaceted mechanism of action. The findings highlight UA's potential as a novel therapeutic option for managing PCOS symptoms, emphasizing the need for further research into its efficacy and safety in clinical applications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.